铁依赖细胞死亡:解锁铁亡作为多发性骨髓瘤治疗的关键
Fatemeh Karimian1, Melika Khademi1, Amirsalar Nikkhah Bahrami2
1Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clinical immunology (Orlando, Fla.)
|July 18, 2025
概括
铁,一种依赖于铁的细胞死亡,显示出作为治疗多发性骨髓瘤 (MM) 的新疗法的希望. 诱导恶性细胞中的铁亡可以增强当前的MM治疗方法并改善患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 铁亡是一种受调节的细胞死亡途径,由铁的积累和脂质过氧化驱动.
- 多发性骨髓瘤 (MM) 是一种血液性癌症,尽管治疗方面取得了进展,但预后不佳.
- 在MM中的恶性细胞表现出对铁亡的敏感性,表明治疗潜力.
研究的目的:
- 审查铁灭的细胞机制.
- 探索铁灭菌在消除多发性骨髓瘤细胞中的作用.
- 评估铁化作为MM治疗策略的有效性,包括与现有药物结合使用.
主要方法:
- 关于铁灭症机制的文献综述.
- 对调查多发性骨髓瘤中铁亡的研究进行分析.
- 检查结合疗法中对铁亡的研究.
主要成果:
- 铁亡是由氧化和抗氧化过程的不平衡引发的,涉及铁和脂质代谢,GPX4发挥着关键作用.
- 多发性骨髓瘤细胞容易受到铁亡诱导的影响.
- 铁生可能是消除MM细胞的有效策略,可能增强像Bortezomib这样的传统治疗方法.
结论:
- 铁死代表了对多发性骨髓瘤的有前途的新疗法.
- 向铁亡可能会克服耐药性,并提高MM的治疗疗效.
- 对基于铁亡的治疗方法的进一步研究可能会对MM患者的护理产生重大影响.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
276
相关概念视频
Necrosis
4.8K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
Overview of Cell Death
7.8K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
